The US Food and Drug Administration has approved the FDA, a new drug, listed as an antibacterial, called Recarbrio, that is used in the treatment of adults with urinary tract infections.
The US administration explained that the new drug is a compound of 3 drugs, namely "Relebacta, Cilastatin, Imipenem", stressing that it was tested on a group of patients, numbering 415 people, to show researchers how effective it is in treating urinary tract infection.
Read also: The causes of urinary tract infections and ways to prevent them
The FDA added that Recarbrio has some of the side effects of "diarrhea, headache, high body temperature and increased liver enzymes", warning of the risk of taking it with Ganciclovir - an antiviral drug -, Valproic - an anti-convulsive drug - and Divalproex - an antiepileptic drug - To avoid seizures, which may result from the interaction of one of them with the new drug.
The US administration confirmed that it is moving forward with developing new safe and effective antibacterial drugs, to give patients more options to combat serious infections.
